Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04866082 |
| Other study ID # |
ASAP-ESICM/ESAIC |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 30, 2021 |
| Est. completion date |
June 30, 2022 |
Study information
| Verified date |
February 2023 |
| Source |
Brno University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Brief Summary: Administration of systemic corticosteroids for patients with severe forms of
severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection are recommended by
several guidelines. In the very beginning of SARS-CoV-2 pandemic the early recommendation by
professional organization was against routine use of corticosteroids for patients with
coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for
patients with refractory or severe form of acute respiratory distress syndrome (ARDS). But
recently after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July
2020) and ensued metaanalysis of World Health Organization (WHO) working group, routine
administration of systemic corticosteroids was revisited. However, there is an ongoing debate
regarding evidence supporting the dose, type of administration (bolus vs. continuous
infusion), timing and type of corticosteroids. Ongoing randomized controlled trials (RCTs)
are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form
of COVID-19. Due to the dynamics of COVID-19 surges and rapid issuing of official
recommendations, daily clinical practice of systemic corticosteroids administration can vary.
An electronic evaluation form containing 20 questions will be sent to European Society of
Intensive Care (ESICM) and European Society of Anaesthesiology and Intensive Care (ESAIC)
members. Participants will be asked to describe their routine clinical practice regarding
administration of systemic corticosteroids among patients with COVID-19 ARDS.
Description:
Brief Summary: Administration of systemic corticosteroids for patients with severe forms of
SARS-CoV-2 infection are recommended by several guidelines. In the very beginning of
SARS-CoV-2 pandemic the early recommendation by professional organization was against routine
use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite
previous data and clinical practice for patients with refractory or severe form of ARDS. But
recently after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July
2020) and ensued metaanalysis of WHO working group, routine administration of systemic
corticosteroids was revisited. However, there is an ongoing debate regarding evidence
supporting the dose, type of administration (bolus vs. continuous infusion), timing and type
of corticosteroids. Ongoing RCTs (Randomized Clinical Trials) are challenging the
recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. Due to
the dynamics of COVID-19 surges and rapid issuing of official recommendations, daily clinical
practice of systemic corticosteroids administration can vary. An electronic evaluation form
containing 20 questions will be sent to European Society of Intensive Care (ESICM) European
Society of Anaesthesiology and Intensive Care (ESAIC) members. Participants will be asked to
describe their routine clinical practice regarding administration of systemic corticosteroids
among patients with COVID-19 ARDS.
